REQUEST A DEMO
Total
USD $0.00
View basket Checkout now
Search more companies

"Usp Zdrowie" Sp. z o.o. (Poland)

Main Activities: Pharmaceutical and Medicine Manufacturing
Secondary Activities: Drugs and Druggists' Sundries Merchant Wholesalers
Full name: "Usp Zdrowie" Sp. z o.o. Profile Updated: August 11, 2024
Buy our report for this company USD 29.95 Most recent financial data: 2023 Available in: English & Polish Download a sample report

Usp Zdrowie Sp. z o.o. is a company located in Warsaw, Poland. It was established in 1992 by Voitek Napiórkowski and has since become a leader in the Polish market for over-the-counter drugs. The company's portfolio includes well-known and respected brands such as Apap, Ibuprom, Gripex, Verdin, Stoperan, and Xenna.

Headquarters
Ul. Poleczki 35
Warsaw; Mazowieckie; Postal Code: 02-822

Contact Details: Purchase the "Usp Zdrowie" Sp. z o.o. report to view the information.

Website: http://www.usp.pl

Basic Information
Total Employees:
Purchase the "Usp Zdrowie" Sp. z o.o. report to view the information.
Outstanding Shares:
Purchase the "Usp Zdrowie" Sp. z o.o. report to view the information.
Registered Capital:
Purchase the "Usp Zdrowie" Sp. z o.o. report to view the information.
Financial Auditors:
Purchase the "Usp Zdrowie" Sp. z o.o. report to view the information.
Incorporation Date:
February 01, 2010
Key Executives
Purchase this report to view the information.
President
Purchase this report to view the information.
Vice President
Purchase this report to view the information.
Supervisory Board Member
Purchase this report to view the information.
Supervisory Board Member
Purchase this report to view the information.
Supervisory Board Member
Ownership Details
Purchase this report to view the information.
100%
Subsidiaries
Healthily Sp. z o.o.
100%
Selfish 3 Sp. z o.o.
24.97%
Company Performance
Financial values in the chart are available after "Usp Zdrowie" Sp. z o.o. report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency PLN. Absolute financial data is included in the purchased report.
Net sales revenue
16.13%▲
Total operating revenue
16.11%▲
Operating profit (EBIT)
32.37%▲
EBITDA
32.88%▲
Net Profit (Loss) for the Period
31.36%▲
Total assets
28.31%▲
Total equity
27.41%▲
Operating Profit Margin (ROS)
1.6%▲
Net Profit Margin
1.35%▲
Return on Equity (ROE)
0.64%▲
Quick Ratio
-0.14%▼
Cash Ratio
-0.54%▼

Similar companies

Zaklady Farmaceutyczne "Polpharma" S.A.
 
Lek S.A.
Bayer Sp. z o.o.
 
"Roche Polska" Sp. z o.o.
Teva Operations Poland Sp. z o.o.
 
Adamed Pharma S.A.
Sanofi Sp. z o.o.
 
"Fresenius Kabi Polska" Sp. z o.o.
Novo S.A.
 
Warszawskie Zaklady Farmaceutyczne Polfa S.A. Skrot: Warszawskie Zaklady Farmaceutyczne Polfa S.A. Polfa Warszawa S.A.
"Przedsiebiorstwo Produkcji Farmaceutycznej Hasco - Lek" S.A.
 

Related EMIS Industry Reports

To view more information, Request a demonstration of the EMIS service

USD 29.95
Buy this company report
Need ongoing access to company, industry or country information?
Request a demo